Ysios Capital, Spain’s largest and leading European venture capital firm specialised in the biotechnology sector, announces today that it has closed its third fund, Ysios BioFund III (YBF III) at...
Read moreOryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, presented today...
Read moreUn trabajo publicado en Cell Reports descifra el mapa transcriptómico de la esclerosis del hipocampo, un hallazgo clave para el diagnóstico de la epilepsia del lóbulo temporal. Los resultados ident...
Read moreManufacturing partnership enables suspension-based manufacture of gene therapies and viral vector-based vaccines
Read moreLa spin off de la Universidad de Santiago de Compostela, AFFINImeter, dentro de un consorcio con 13 universidades europeas y una multinacional británica para desarrollar una infraestructura de apo...
Read moreOryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, today reported ...
Read moreThe summer period has begun with some important news in the sector. Two of the most important biotech crowdfunding rounds of the year have been closed. And, Barcelona has announced the creation of a n...
Read moreSeqera Labs – the leading provider of data orchestration and workflow software for life sciences – announces it has raised $5.5 million USD in seed funding.
Read moreAlgenex SL, a biotech company backed by Cleon Capital and Columbus Ventures delivering disruptive technologies for recombinant biologics production, and FATRO S.p.A, a leader in the field of veteri...
Read moreFlomics Biotech continues to dedicate resources in the battle against the COVID19 pandemic. Last year Flomics announced the release of -FlomicsCOVID19– a cloud-based Next Generation Sequencing (N...
Read moreBreast cancer risk is determined by several factors and our genetic constellation can play a big part on it.
Read moreYsios Capital, a leading Spanish biotechnology venture capital firm, has announced that its portfolio company Aura Biosciences Inc. has priced its initial public offering (IPO) and is trading on th...
Read more